Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162293 | 0.82 | LMNA (0.47) | LMNACYP2C19HIF1A | |
| SCHEMBL1048643 | 0.82 | LMNA (0.44) | LMNACYP2C19HIF1A | |
| SCHEMBL7607980 | 0.82 | LMNA (0.47) | LMNACYP2C19HIF1A | |
| SCHEMBL29665118 | 0.81 | CYP2C19 (0.36) | LMNACYP2C19HIF1A | |
| SCHEMBL7056057 | 0.81 | CYP2C19 (0.36) | LMNACYP2C19HIF1A | |
| SCHEMBL8720205 | 0.81 | CYP2C19 (0.36) | LMNACYP2C19HIF1A | |
| SCHEMBL7095049 | 0.80 | LMNA (0.36) | LMNACYP2C19HIF1A | |
| SCHEMBL5033195 | 0.80 | LMNA (0.45) | LMNACYP2C19HIF1A | |
| SCHEMBL9171058 | 0.80 | LMNA (0.53) | LMNACYP2C19HIF1A | |
| SCHEMBL10318442 | 0.79 | LMNA (0.44) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900632-B1 | PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL | GE HEALTHCARE AS (NO) | 2019-10-30 | — | — | EP | disclosed |
| EP-2900631-B1 | PREPARATION OF IOFORMINOL, AN X-RAY CONTRAST AGENT | GE HEALTHCARE AS (NO) | 2018-11-14 | — | — | EP | disclosed |
| EP-2935204-B1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2018-09-05 | — | — | EP | disclosed |
| US-9938233-B2 | Purification of X-ray contrast agents | GE HEALTHCARE AS (NO) | 2018-04-10 | — | — | US | disclosed |
| US-9884808-B2 | Preparation of an intermediate compound of ioforminol | GE HEALTHCARE AS (NO) | 2018-02-06 | — | — | US | disclosed |
| US-9827334-B2 | Preparation of ioforminol, an x-ray contrast agent | GE HEALTHCARE AS (NO) | 2017-11-28 | — | — | US | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-20160304440-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2016-10-20 | — | — | US | disclosed |
| EP-2935204-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE Healthcare AS (NO) | 2015-10-28 | — | — | EP | disclosed |
| US-20150265727-A1 | PREPARATION OF IOFORMINOL, AN X-RAY CONTRAST AGENT | GE HEALTHCARE AS (NO) | 2015-09-24 | — | — | US | disclosed |
| US-20150246871-A1 | PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL | GE HEALTHCARE AS (NO) | 2015-09-03 | — | — | US | disclosed |
| EP-2900632-A1 | PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL | GE HEALTHCARE AS (NO) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900631-A1 | PREPARATION OF IOFORMINOL, AN X-RAY CONTRAST AGENT | GE Healthcare AS (NO) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| US-8920780-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2014-12-30 | — | — | US | disclosed |
| EP-2178568-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2014-07-02 | — | — | EP | disclosed |
| WO-2014099214-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2014-06-26 | — | — | WO | disclosed |
| US-20100322868-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-23 | — | — | US | disclosed |
| EP-2178568-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191422-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
| US-20150246871-A1 | PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL | IPO11, IPO4, IPO8 | LMNA 1586/4885CYP2C19 427/4885HIF1A 2857/4885 |
| US-20160304440-A1 | PURIFICATION OF X-RAY CONTRAST AGENTS | TMEM97, OGFR, TMEM120A | LMNA 721/4885CYP2C19 3870/4885HIF1A 1865/4885 |
| US-20100322868-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
| US-20150265727-A1 | PREPARATION OF IOFORMINOL, AN X-RAY CONTRAST AGENT | FOSB, OGFOD1, FLNB | LMNA 878/4885CYP2C19 267/4885HIF1A 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.